Table 2.

Treatment characteristics for patients with IDC-P identified in the SEER database, diagnosed between 2000 and 2020

Variable	Number (% of Cohort; n = 945)
Definitive surgery performed?*
Yes	511 (54.1%)
No	434 (45.9%)
Surgery performed
Pelvic exenteration	6 (0.6%)
Laser ablation	2 (0.2%)
No surgery	252 (26.7%)
Not specified	3 (0.3%)
Radical prostatectomy	499 (52.8%)
Subtotal prostatectomy	6 (0.6%)
TURP (with or without concurrent Laser Ablation)	117 (18.1%)
Unimodal surgical treatment
Yes	434 (45.9%)
No	511 (54.1%)
Number of lymph nodes surgically removed
None	507 (53.7%)
1–3	94 (9.9%)
≥ 4	280 (29.6%)
Unknown	64 (6.8%)
Unimodal radiotherapy (RT) treatment
Yes	134 (14.2%)
No	811 (85.8%)
Type of RT administered
Brachytherapy	12 (1.3%)
External beam RT (EBRT)	239 (25.3%)
EBRT with either brachytherapy or radioisotopes	17 (1.8%)
Radioisotopes	3 (0.3%)
No RT administered	674 (71.3%)
Chemotherapy administered
Yes	23 (2.4%)
No/unknown	922 (97.6%)

Note that the SEER database codes the chemotherapy variable as either “Yes” or “No/Unknown;” more information is not available regarding chemotherapy

^*Definitive surgery is defined as either radical or total prostatectomy, or pelvic exenteration